CRISPR Meets LNPs: A New Era In Cell And Gene Therapies

Cell and gene therapies are undergoing a transformative shift, propelled by the urgent need for scalable, cost-effective, and safe gene editing and delivery technologies. Among the most promising developments is the move away from traditional viral vectors, which, despite their effectiveness, come with significant drawbacks. These include high production costs, complex regulatory hurdles, and potential safety concerns. In response to these challenges, lipid nanoparticles (LNPs) are emerging as a powerful non-viral delivery platform. LNPs offer a scalable and efficient solution for gene editing, suitable for both ex vivo modification of T cells and in vivo gene therapy applications. In this webinar, experts from Cytiva and Integrated DNA Technologies (IDT) will present compelling new data showcasing the potential of CRISPR-LNPs for multiplex gene editing in primary human T cells. Utilizing the scalable NanoAssemblr™ microfluidics platform, researchers formulated LNPs with SpCas9 mRNA, Alt-R™ CRISPR-Cas9 single guide RNAs (sgRNAs), and a donor single-stranded oligodeoxynucleotide (ssODN) template.

Discover how the results demonstrated high-efficiency gene editing, robust homology-directed repair (HDR), and excellent post-editing cell viability.